Metabolic Associated Steatohepatitis Liver Disease (MASLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), represents a significant public health issue, often progressing silently to severe liver damage, highlighting the need for early detection and treatment. While liver biopsy has long been considered the gold standard for identifying liver fibrosis and evaluating MASLD severity, its substantial drawbacks cannot be overlooked. Recently, noninvasive methods have gained attention for predicting MASLD and liver fibrosis. Herein, we would like to summarize noninvasive diagnostic approaches, focusing on serologic tests and imaging techniques, offering insights into their clinical applicability and advancing patient care in MASLD management.